home / stock / ntra / ntra news


NTRA News and Press, Natera Inc. From 03/14/22

Stock Information

Company Name: Natera Inc.
Stock Symbol: NTRA
Market: NASDAQ
Website: natera.com

Menu

NTRA NTRA Quote NTRA Short NTRA News NTRA Articles NTRA Message Board
Get NTRA Alerts

News, Short Squeeze, Breakout and More Instantly...

NTRA - CareDx Wins $44.9M in Damages in False Advertising Trial Against Natera; Natera Intentionally Deceived Transplant Community

SOUTH SAN FRANCISCO, Calif., March 14, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers...

NTRA - Natera Executives and Board to Take Pay in Stock Instead of Cash

Natera Executives and Board to Take Pay in Stock Instead of Cash PR Newswire Leadership, Board to Exchange Cash Compensation for Shares AUSTIN, Texas , March 14, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA te...

NTRA - Natera Shareholder Notice

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Natera To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - March 13, 2022) - Faruqi & Faruqi, LLP, a leading national securities law firm, is ...

NTRA - HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Investigating Natera, Inc. (NTRA) for Possible Securities Law Violations, Investors With Significant Losses Encouraged To Contact Firm

San Francisco, California--(Newsfile Corp. - March 11, 2022) - Hagens Berman urges Natera, Inc. (NASDAQ: NTRA) investors who suffered significant losses to submit your losses now . The firm is investigating possible violations of the securities laws. Visit: www.hbsslaw.com/investor-frau...

NTRA - Natera Achieves Milestone of Enrolling First 1,000 Patients in its BESPOKE CRC Study

Natera Achieves Milestone of Enrolling First 1,000 Patients in its BESPOKE CRC Study Clinical utility study in stage I-IV colorectal cancer (CRC) evaluates how adjuvant treatment decisions are impacted by using the Signatera™ MRD test PR Newswire AUSTIN, Tex...

NTRA - NTRA INVESTIGATION: Hagens Berman, National Trial Attorneys, Investigating Natera, Inc. (NTRA) For Possible Securities Law Violations, Investors With Significant Losses Encouraged to Contact Firm

SAN FRANCISCO, CA / ACCESSWIRE / March 10, 2022 / Hagens Berman urges Natera, Inc. (NASDAQ:NTRA) investors who suffered significant losses to submit your losses now . The firm is investigating possible violations of the securities laws. Visit: www.hbsslaw.com/investor-fraud/NTRA Co...

NTRA - Why Is Natera (NTRA) Stock Up Today?

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Shares of Natera (NASDAQ: NTRA ) plunged lower by as much as 40% yesterday after Hindenburg Research released a short report on the company. The report alleged that Natera engaged in several fraudulent practices c...

NTRA - NTRA, RKDA and ACMR among mid-day movers

Gainers: AgriFORCE Growing Systems (NASDAQ:AGRI) +159%. Arcadia Biosciences (NASDAQ:RKDA) +44%. CEA Industries (NASDAQ:CEAD) +32%. Enservco (NYSE:ENSV) +30%. Ebix (NASDAQ:EBIX) +27%. Pop Culture Group (NASDAQ:CPOP) +26%. Natera (NASDAQ:NTRA) +24%. Kala Pharmaceuticals (NASDAQ:KALA) +21%. iPow...

NTRA - Kala, Natera top healthcare gainers; Sunshine Biopharma, Myomo lead losers' pack

Gainers: Kala Pharmaceuticals (NASDAQ:KALA) +20%. Natera (NASDAQ:NTRA) +17%. Chemomab Therapeutics (NASDAQ:CMMB) +13%. Selecta Biosciences (NASDAQ:SELB) +11%. Longeveron (NASDAQ:LGVN) +7%. Losers: Sunshine Biopharma (NASDAQ:SBFM) -32%. My...

NTRA - Natera gains after company, analyst defends following plunge on short report

Natera Inc. (NASDAQ:NTRA) shares rose 14%, paring almost half of the 33% decline on Wednesday, following a short report from Hindenburg Research on the diagnostics testing company. Several analysts on including Canaccord , Raymond James, Morgan Stanley and Baird came out in defense ...

Previous 10 Next 10